Share: 
Status: 
Active
Rating: 
Average: 4.6 (9 votes)
4.555555

Improving the Treatment and Management of Endometriosis: An Overview of Current and Novel Approaches

Course description

Endometriosis is an estrogen-dependent disease of unknown etiology that frequently results in significant morbidity, severe pelvic pain, multiple surgeries, and impaired fertility. It affects at least 8.5 million women in North America alone and is a leading cause of gynecologic hospitalization and surgery. It is clinically defined as presence of ectopic or extrauterine endometrial or endometrial-like tissue resulting in a sustained inflammatory reaction. Although pharmacologic and surgical treatment options are available, endometriosis can be difficult to manage because many treatments have limited efficacy, while serious side effects of some agents limit long-term treatment or make them inappropriate for some patients. New hormonal agents are in late-stage development and will expand the available treatment options. 

Target Audience

This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with endometriosis.

Learning Objectives

Upon completion of this activity, participants will be better able to:

  1. Describe the efficacy and limitations of available treatments for endometriosis with regard to pain relief
  2. Summarize the safety issues associated with available treatments for endometriosis
  3. Discuss the potential benefits of new hormonal therapies in development for endometriosis

Faculty

 

              

Adam Ofer, MD (Moderator)
Director of Gynecology 
Norwalk Hospital
Norwalk, Connecticut

Lee P. Shulman, MD
Professor of Obstetrics and Gynecology 
Feinberg School of Medicine
Northwestern University
Chicago, Illinois 

            

Sukhbir Sony Singh, MD, FRCSC, FACOG
Associate Professor and Vice-Chair of Gynecology
University of Ottawa
Ottawa, Ontario, Canada

 

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflict of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter

Relationship Identified With:

Adam Ofer, MD

Consultant/Advisor: Myriad Genetics

Speakers Bureau: Myriad Genetics

Lee P. Shulman, MD

Consultant/Advisor: Bayer, Merck, Pfizer, Roche, Sequenom, Natera, and Ariosa

Speakers Bureau: Bayer, Merck, Pfizer, and Roche

Sukhbir Sony Singh, MD, FRCSC, FACOG

Consultant/Advisor: Actavis, Bayer, and AbbVie

Grant/Research Support: Actavis, Bayer, and AbbVie

Speakers Bureau: Actavis, Bayer, AbbVie, and Hologic 

 

Non-Faculty: Sandy Breslow; Brynne Hunter; Lyerka Miller, PhD; and Bernard Abrams, MD hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from AbbVie Inc.

Provider Information

Jointly provided by The Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

  


Course Open Date: July 30, 2015 | Course Expiration Date: July 29, 2016

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to providing continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Journal Distribution

This enduring material has been reviewed and approved by the American Journal of Obstetrics and Gynecology

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use:
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education; Miller Medical Communications, LLC; and AbbVie Inc do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Credits & accreditation
Course summary
Course opens: 
07/30/2015
Course expires: 
07/29/2018
Please login or register to take this course.